Chemeq broadens pipeline with sunscreen product
28 January, 2003 by Melissa TrudingerPerth-based biotech Chemeq has expanded its pipeline with the development of a sunscreen and an after-sun emollient based on its proprietary polymer chemistry platform.
Adult stem cells hold promise in future MS therapy
21 January, 2003 by Susan WilliamsonResearchers at Sydney's St Vincent's Hospital have found for the first time that adult stem cells can be differentiated into the white matter forming cells of the brain, the oligodendrocytes.
Arthritis vaccine breakthrough claimed by Qld team
16 January, 2003 by Pete YoungAn Australian research team is claiming a breakthrough in developing a therapeutic vaccine against autoimmune diseases including rheumatoid arthritis.
Stem cell centre swings into action as funding finally approved
10 January, 2003 by Melissa TrudingerActivities at the National Stem Cell Centre were delayed by an inquiry into allegations that it was given preferential treatment during bidding for Commonwealth funding, the centre's chief operating officer, Dr Dianna DeVore, said today, but Prime Minister John Howard's December 24 announcement that an independent report found no basis to the allegations was "a wonderful Christmas present".
Researchers rejoice as stem cell Bill passes
06 December, 2002 by Graeme O'NeillAustralian stem-cell researchers are elated at yesterday's decisive Senate vote in favour of a Bill to permit research on stem cells from surplus IVF embryos.
Stem cell patent purchase 'clear path to market': BresaGen
18 November, 2002 by Graeme O'NeillAdelaide biotechnology company BresaGen has fitted the keystone into the archway of its ambition to be a substantial player in embryonic stem cell (ES cell) therapy, by acquiring valuable patents on the methodology for isolating pluripotent stem cells.
Opponent of ES cell research broadens attack
15 November, 2002 by Pete YoungEmbryonic stem cell research opponent Senator Ron Boswell has this week widened his criticism of the CEO-designate of the National Stem Cell Centre, Prof Alan Trounson, to include other high-profile members of the biotech community.
Vision BioSystems: 'We've arrived'
12 November, 2002 by Melissa TrudingerMelbourne instrument manufacturer Vision BioSystems is claiming early international success for its new Bond immunochemistry and in situ hybridisation staining system.
Back to microbes
11 November, 2002 by Melissa TrudingerWith all the excitement over the human genome and its potential for increasing understanding of human disease, microbial disease research has slipped out of the limelight.
One cell is enough for forensic DNA fingerprinting
31 October, 2002 by Melissa TrudingerA new technique for fingerprinting DNA from a single cell may have tremendous potential for forensic investigations and other applications, allowing individuals to be identified from just one cell.
Senate committee divided on stem cells
25 October, 2002 by Pete YoungThe outcome of a Senate committee inquiry into proposed embryonic human stem cell research legislation suggests it may require extensive surgery to pass a Senate vote.
Stem cells workshop set down for UNSW
10 October, 2002 by Melissa TrudingerThe University of NSW is holding a workshop on stem cells on November 19th for all NSW researchers working with or interested in working with stem cells.
Speaking the language of bacteria
02 October, 2002 by Graeme O'NeillMicrobial geneticist Prof Bonnie Bassler of Princeton University is a sort of bacterial linguist -- she studies how bacteria, the simplest living organisms, communicate.
Humans vs microbes: the ASM goes to war
01 October, 2002 by Graeme O'NeillMicrobiology is in ferment, says Dr Jan Tennent, and the next decade is likely to see major gains in the perennial war between humans and their microbial nemeses -- viruses, bacteria and parasites.
ES Cell refocuses cell line marketing strategy
27 September, 2002 by Pete YoungSingapore-based company ES Cell International is changing the marketing strategies for its human embryonic stem cell lines because of researchers' reluctance to part with intellectual property.
